Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
312,5 USD | -0,71 % | +0,75 % | +8,49 % |
Resumen de negocios
- venta de fármacos (94,2%): medicamentos para el tratamiento del cáncer, trastornos metabólicos, enfermedades óseas, insuficiencia renal, hemofilia, etc;
- otros (5,8%): principalmente royalties.
Estados Unidos representa el 70,3% de las ventas netas.
Número de empleados: 26 700
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Human Therapeutics
95,5
%
| 24 801 | 94,2 % | 26 910 | 95,5 % | +8,50 % |
Other
4,5
%
| 1 522 | 5,8 % | 1 280 | 4,5 % | -15,90 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
70,3
%
| 18 595 | 70,6 % | 19 806 | 70,3 % | +6,51 % |
Rest of World
29,6
%
| 7 655 | 29,1 % | 8 337 | 29,6 % | +8,91 % |
Canada
0,2
%
| 73 | 0,3 % | 47 | 0,2 % | -35,62 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23/10/19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
Chief Tech/Sci/R&D Officer | 53 | - | |
Esteban Santos
COO | Chief Operating Officer | 56 | 01/01/07 |
Nancy Grygiel
CMP | Compliance Officer | 56 | 01/01/15 |
Mike Zahigian
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/01 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/05 |
Darryl Sleep
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/18 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/06/23 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03/02/17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14/10/16 |
Robert Williams
BRD | Director/Board Member | 75 | 17/10/14 |
Robert Eckert
BRD | Director/Board Member | 69 | 01/01/03 |
Ronald Sugar
BRD | Director/Board Member | 75 | 22/07/10 |
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/06 |
Wanda Austin
BRD | Director/Board Member | 69 | 24/10/17 |
Tyler Jacks
BRD | Director/Board Member | 63 | 01/01/12 |
Omar Ishrak
BRD | Director/Board Member | 68 | 30/07/21 |
Greg Garland
BRD | Director/Board Member | 66 | 16/10/13 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 536 434 692 | 535 107 021 ( 99,75 %) | 0 | 99,75 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
BEIGENE, LTD. 19.80% | 246 269 426 | 19.80% | 2 978 709 976 $ |
NEUMORA THERAPEUTICS, INC. 22.26% | 35 368 653 | 22.26% | 320 439 996 $ |
4 910 000 | 5.50% | 105 270 400 $ | |
VIGIL NEUROSCIENCE, INC. 8.53% | 3 206 281 | 8.53% | 8 272 205 $ |
100 993 | 0.67% | 2 139 032 $ |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Amgen Manufacturing Ltd. (Bermuda)
| |
Amgen Technology Ltd.
Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The company is located in Bermuda. |
Biotechnology
|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+8,49 % | 168 mil M | |
+32,09 % | 693 mil M | |
+29,39 % | 584 mil M | |
-1,34 % | 372 mil M | |
+20,34 % | 332 mil M | |
+7,39 % | 294 mil M | |
+14,25 % | 239 mil M | |
-3,03 % | 211 mil M | |
+10,02 % | 210 mil M | |
-0,52 % | 162 mil M |
- Bolsa de valores
- Acciones
- Acción AMGN
- Empresa Amgen Inc.